Compare CVLT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLT | BLCO |
|---|---|---|
| Founded | 1996 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | 2006 | 2022 |
| Metric | CVLT | BLCO |
|---|---|---|
| Price | $121.72 | $16.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 14 |
| Target Price | ★ $193.83 | $17.31 |
| AVG Volume (30 Days) | ★ 647.6K | 399.7K |
| Earning Date | 01-27-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | $1,095,835,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $19.22 | $8.08 |
| Revenue Next Year | $12.47 | $5.77 |
| P/E Ratio | $69.10 | ★ N/A |
| Revenue Growth | ★ 22.02 | 6.23 |
| 52 Week Low | $114.47 | $10.45 |
| 52 Week High | $200.69 | $18.99 |
| Indicator | CVLT | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 60.98 |
| Support Level | $119.27 | $16.39 |
| Resistance Level | $125.65 | $17.41 |
| Average True Range (ATR) | 3.67 | 0.46 |
| MACD | 1.71 | 0.06 |
| Stochastic Oscillator | 64.86 | 72.71 |
CommVault Systems Inc provides data and information management software applications and services. The firm sells software licenses and services to large global enterprises, small- and midsize businesses, and government agencies through both its salesforce and its network of reseller partners. Its software solutions include Cleanroom Recovery, HyperScale X, Air Gap Protect, Compliance, Cloud Rewind, and Clumio Backtrack. The company operates in the United States and exports to many other countries.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.